Replies to post #8083 on Momenta Pharmaceuticals, Inc. (MNTA)

[oldberkeley]

Teva raises price of Copaxone by 15%...the price hike suggests that Teva feels safe about its competitive position

Or that they're going to try and make as much from it while they still can.

[y3maxx]

""despite the launch of Gilenya, an oral treatment made by Novartis AG (NYSE:NVS; LSE: NOV; SWX: NOVZ), in late 2010""

...Perhaps NVS cares very little of M copax success because of Gilenya?

...Who really knows just how supportive NVS is with M copax at the FDA?